GlaxoSmithKline (LSE:GSK)
GlaxoSmithKline is one of the world's leading pharmaceutical research companies. The company was created out of the merger between GlaxoWellcome and SmithKline Beecham in 2000.
About
Last updated 20-01-2020, 04:51:25pm GMTRelated Articles
-
Have £3k to invest? 3 healthcare stocks I’d buy for 2020
Ageing populations and fast-growing emerging markets make these stocks a buy, says Roland Head. Read More »
-
2 FTSE 100 dividend stocks I’d buy and hold for the next 10 years
These two FTSE 100 (INDEXFTSE:UKX) shares could offer income investing potential in my opinion. Read More »
-
I think this FTSE 100 dividend stock could double investors’ money
This FTSE 100 company is set to benefit tremendously from global growth, and investors should be well rewarded. Read More »
-
Looking for dividend stocks for retirement? I think you’ll love these FTSE 100 companies
When it comes to dividend stocks for retirement, you need to be selective, says Edward Sheldon. Now is not the time to be taking... Read More »
-
Investment lessons from Warren Buffett and the man who taught him how to make millions
Even the Oracle of Omaha had a mentor in Benjamin Graham, and you can learn something from both of them. Read More »
-
A 4.5% FTSE 100 dividend yield I’d buy for my ISA and never sell!
Royston Wild explains why this FTSE 100 dividend stock is a top buy today. Read More »
-
Why I think the GSK share price could keep rising in 2020
The GlaxoSmithKline plc (LON: GSK) share price has hit an 18-year high. Roland Head remains bullish. Read More »
-
How I’d invest in 2020 to retire early
I'd say high-quality and consistent growth is key in stock selection. Read More »
-
This is how much £1K invested in GSK shares 5 years ago would be worth today
GlaxoSmithKline plc (LON: GSK) is a popular stock. But has it been a good investment? Read More »
-
Forget the Cash ISA! I’d buy this FTSE 100 dividend stock to retire on
With its healthy cash flows and defensive market position, this FTSE 100 stock is worth owning in your retirement portfolio, says Rupert Hargreaves. Read More »